ArticleBMC research notes2025
A pilot study on a heterologous prime-boost approach for inducing an immune response against double-layered human rotavirus particles.
Article in BMC research notes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveRotavirus is known for its pathogenicity in children under the age of five, causing severe gastroenteritis with concerning mortality and morbidity rates in endemic regions. The complex, three-layered capsid of this pathogen is a substantial field of study, and deepening our understanding, particularly of double-layered particles (DLPs), is crucial for advancing various rotavirology areas, such as vaccine development, pathogenesis, host-virus interactions, and diagnostic research. In this pilot study, we designed and evaluated three immunostimulation regimens to generate the highest level of anti-VP6 antibody in vivo for a range of downstream applications, which may require these antibodies as a starting point for further investigation.
resultsThis study indicated that immune stimulation can vary based on the combination of antigens and the order in which they are introduced into the host. According to our findings, a heterologous regimen composed of recombinant VP6 protein with complete Freund's adjuvant as the priming shot and rotavirus particles with incomplete Freund's adjuvant as the booster shot could elicit an antibody response at least two-fold stronger than the other homologous regimens applied in the present study. This preliminary observation suggests a high-yielding yet cost-effective protocol to access abundant anti-VP6 polyclonal antibodies as a base for different DLP-relying research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.